April 19, 2017 06:56 PM EDT
R&D

Ab­b­Vie grap­ples with an­oth­er set­back as 2 PhI­II tri­als for its PARP veli­parib flop

John Carroll

Editor & Founder

Up un­til now, PARP in­hibitors have been blaz­ing a broad, long trail of suc­cess in the clin­ic, with Lyn­parza, Rubra­ca and now Ze­ju­la hit­ting a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times